Antifibrinolytics—aprotinin in cardiac surgery

Starr P. The liberal years. In: The social transformation of American medicine. New York: Basic Book Inc., 1982, pp. 335–378.

Stoney WS. Evolution of cardiopulmonary bypass. Circulation 2009; 119: 2844–2853. doi:10.1161/CIRCULATIONAHA.108.830174

Brown IW Smith WW. Hematologic problems associated with the use of extracorporeal circulation for cardiovascular surgery. Ann Intern Med 1958; 49: 1035–1048. doi:10.7326/0003-4819-49-5-1035

Phillips LL Malm JR Deterling MD. Coagulation defects following extracorporeal circulation. Ann Surg 1963; 157: 317–326. doi:10.1097/00000658-196303000-00001

Rothnie NG Norman AG Steele M , et al. Changes in blood coagulation due to perfusion for cardiac surgery. Br J Surg 1960; 48: 272–281. doi:10.1002/bjs.18004820907

Osborn JJ MacKenzie R Shaw A , et al. Cause and prevention of hemorrhage following extracorporeal circulation. Surg Forum 1956; 6: 96–100.

Von Kaulla KN Swan H. Clotting deviations in man during cardiopulmonary bypass: Fibrinolysis and circulating anticoagulant. J Thorac Surg 1958; 36: 519–533. doi:10.1016/S0096-5588(20)30129-X

Tice DA Reed GE Clauss RH , et al. Hemorrhage due to fibrinolysis occurring with open-heart operations. J Thorac Cardiovasc Surg 1963; 46: 673–679. doi:10.1016/S0022-5223(19)33639-6

Mammen EF. Natural proteinase inhibitors in extracorporeal circulation. Ann N Y Acad Sci 1968; 146: 754–762. doi:10.1111/j.1749-6632.1968.tb20334.x

Westaby S. Aprotinin in perspective. Ann Thorac Surg 1993; 55: 1033–1041. doi:10.1016/0003-4975(93)90149-c

Kraut H Frey EK Werle E. Über die Inaktivierung des Kallikreins. (VI. Mitteilung über dieses Kreislaufhormon.). Biol Chem 1930; 192: 1–21. doi:10.1515/bchm2.1930.192.1-3.1

Smith M Kocher HM Hunt BJ. Aprotinin in severe acute pancreatitis. Int J Clin Pract 2010; 64: 84–92. doi:10.1111/j.1742-1241.2008.01899.x

Royston D Taylor KM Bidstrup BP , et al. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987: 1289–1291. doi:10.1016/S0140-6736(87)91190-1

Bidstrup BP Royston D Taylor KM , et al. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 1989; 97: 364–372. doi:10.1016/S0022-5223(19)34573-8

List of approved NDAs for biological products that were deemed to be BLAs on March 23, 2020, https://www.fda.gov/media/119229/download (accessed 6 June 2025).

McMullan V Alston RP. The effect of the suspension of the license for aprotinin on the care of patients undergoing cardiac surgery. J Cardiothorac Vasc Anesth 2010; 24: 418–421. doi:10.1053/j.jvca.2009.10.028

Cosgrove DM 3rd Heric B Lytle BW , et al. Aprotinin therapy for reoperative myocardial revascularization: A placebo-controlled study. Ann Thorac Surg 1992; 54: 1031–1036. doi:10.1016/0003-4975(92)90066-d

Fergusson D Glass KC Hutton B , et al. Randomised controlled trial of aprotinin in cardiac surgery: Could clinical equipoise have stopped the bleeding? Clin Trials 2005; 2: 218–232. doi:10.1191/1740774505cn085oa

Fergusson DA Hébert PC Mazer CD , et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Eng J Med 2008; 358: 2319–2331. doi:10.1056/NEJMoa0802395

Spiess BD. Pro: The practice of cardiac anesthesia has changed after the withdrawal of aprotinin. J Cardiothorac Vasc Anesth 2010; 24: 875–878. doi:10.1053/j.jvca.2010.07.009

De Hert S Ouattara A Royston D , et al. Use and safety of aprotinin in routine clinical practice. A European postauthorisation safety study conducted in patients undergoing cardiac surgery. Eur J Anaesthesiol 2022; 39: 685–694. doi:10.1097/EJA.0000000000001710